Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease. The company announced that it has licensed a US patent from the University of Miami that has widespread therapeutic indications for heart diseases. This acquisition fits in perfectly with the existing lineup and should prove beneficial to patients and shareholders.
